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GLP-1 AND GLP-2 ARE SYNTHESIZED by posttranslational processing of proglucagon in the L cell of the distal gut and are coreleased into the circulation in response to enteral nutrition (11, 33) . These peptide hormones act in concert to regulate nutrient assimilation; GLP-1 is highly insulinotropic and a potent inhibitor of gastrointestinal (GI) motility, effects that function in concert to limit postprandial glycemic excursions (5, 13, 24, 38) , whereas GLP-2 promotes nutrient absorption by increasing the growth and function of the small intestinal epithelium (6, (13) (14) (15) . However, although a GLP-1 receptor (GLP-1R) agonist is in the clinic for the treatment of Type 2 diabetes mellitus (4) , and GLP-2 is in late-stage clinical trials for the treatment of short bowel syndrome (23) , the mechanisms by which the glucagon-like peptides exert their effects on the gut remain poorly understood.
One major question regarding the actions of both GLP-1 and GLP-2 on the GI tract is the relative importance of the local enteric nervous system (ENS). GLP-1R expression has been demonstrated in the stomach and small and large intestine, as well as in the nodose ganglion of the vagus nerve (7, 30) . Although the exact cellular localization of the GLP-1R within the GI tract has not been described, several studies have indicated that the effects of GLP-1 on gastric vs. intestinal motility are mediated through distinct mechanisms. Hence, vagal deafferentation prevents the inhibitory effect of GLP-1 on antral motility in rats (21) , implicating the vagus in the gastric actions of GLP-1, although this does not appear to be the case in pigs (28) . However, in the small intestine, adrenergic blockers antagonize the inhibitory actions of GLP-1 (19) , indicative of local effects to inhibit excitatory cholinergic motoneurons. Nonetheless, one study has demonstrated that GLP-1 does not affect contractility in isolated gut segments (45) , suggesting that, despite expression of the GLP-1R, this peptide does not directly modulate intestinal motility.
Unlike the GLP-1R, the glucagon-like peptide 2 receptor (GLP-2R) has been localized within the GI tract to a subset of enteroendocrine cells, as well as to subepithelial myofibroblast cells in the mucosa and neurons in the ENS (3, 20, 32, 48) . Initial studies suggested a role for the ENS GLP-2R in intestinal growth through the demonstration that tetrodotoxin prevents GLP-2-mediated activation of c-fos in small intestinal crypt cells (3) . However, the GLP-2R has recently been localized to ENS neurons expressing vasoactive intestinal peptide (VIP) and endothelial nitric oxide synthase, where it is suggested to mediate GLP-2-induced gut blood flow (20) . Nonetheless, GLP-2 has recently been reported to inhibit gastric emptying in humans and pigs (29, 47) , although the findings are controversial (39) , possibly because of reduced potency compared with GLP-1 (29) . Furthermore, although direct inhibitory effects of GLP-2 on large intestinal motility have been demonstrated (10) , it has been suggested that its effects on the small intestine are mediated through GLP-1 (5). In addition, the exact localization within the GI tract of the GLP-2R mediating these effects has not been determined.
To determine the role of the ENS in the actions of GLP-1 and GLP-2 on the GI tract, we have employed a mouse model of enteric nervous deficit, the glial cell line-derived neurotropic factor family receptor ␣2 (GFR␣2) knockout (KO) mouse. GFR␣2 is a member of a family of co-receptors for RET signaling that are required for both colonization of the devel-oping gut by neuronal precursor cells and subsequent tropic support of these neurons (1, 22) . In contrast to the lethality of RET-null or other glial cell line-derived neurotropic factor-null mice (17) , GFR␣2 KO is associated with a partial deficit of parasympathetic innervation and a 35% reduction in cholinergic fiber and substance P (SP) soma density in the myenteric plexus, resulting in reduced but not abrogated GI transit rates in vivo (36, 37) . We therefore hypothesized that these deficits in enteric innervation would result in an impaired tropic response to GLP-2 and attenuated inhibition of gut motility by GLP-1 and/or GLP-2.
METHODS
Animals. GFR␣2 KO mice (C57Bl/6 ϫ 129Sv/J) were a generous gift from Dr. J. Milbrandt (Washington University School of Medicine, St. Louis, MO). Briefly, these mice were generated by homologous recombination of the first coding exon with an enhanced green fluorescent protein cassette, thereby interrupting the GFR␣2 coding sequence. GFR␣2 genotype was determined by PCR with the following primers at an annealing temperature of 60°C: common forward, 5Ј-GGCGGGATCTCCGCATTGGATTT; wild-type (WT) reverse, 5Ј-AGAAGGCGTTTGCCAAGATCATGTTAA; KO reverse, 5Ј-CCCT-GAGCATGATCTTCCATCACGTCG. Mice were housed in standard, pathogen-free conditions under a constant light-dark cycle and were fed Teklad rodent chow wet mash to prevent bowel obstruction (unpublished data) and promote normal growth, as reported for an independent line of GFR␣2 KO mice (36) . All experiments were approved by the Animal Care Committee of the University of Toronto.
Chronic GLP-2 administration study. Age-and sex-matched GFR␣2 WT, heterozygous (HT), and KO littermates were administered 0.15 g/g body wt human [Gly 2 ]GLP-2 (Peptidec Technologies, Pierrefonds, QC, Canada) or an equivalent volume of PBS subcutaneously every 24 h for 14 days, and 3 h before euthanasia on day 15, as reported previously (6, 14, 15, 44) . [Gly 2 ]GLP-2 is a degradationresistant analog of GLP-2 that has a longer half-life in vivo than the native peptide (44) . Some animals were also injected with 100 mg/kg 5-bromo-2-deoxyuridine (BrdU) ip in PBS 1 h before death. Following anesthesia with isoflurane and exsanguination, the small and large intestines were cleaned and weighed, and whole jejunal segments, as well as microdissected jejunal tunica muscularis, were collected for further analysis. The presence of both the myenteric and the submucus plexus in the microdissected tissue was confirmed by demonstration of two morphometrically distinct layers of neurofilament-positive neurons and cell bodies (data not shown).
Morphometry, histochemistry, and immunohistochemistry. As the greatest effects of GLP-2 tropic actions are observed in the jejunum (46) , all growth analyses were conducted in this tissue. Two-centimeter segments of midjejunum (12 cm distal to the pyloric sphincter) were cut into four equal segments, fixed in 10% neutral buffered formalin overnight and transferred to ethanol prior to paraffin embedding (to make n ϭ 1). Embedded tissue was cut into crosssections which were mounted and stained with hematoxylin and eosin. Morphometric analysis was performed using a Zeiss microscope with Axio Vision software (Carl Zeiss Canada, Don Mills, ON, Canada). Villus heights and crypt depths were obtained by blinded measurements of the 4 tissue cross-sections (to make n ϭ 1), with at least 50 and 30 determinations, respectively, per mouse (6, 14, 15) . Cell width and height were determined for five cells per villus across ten villi per mouse (i.e., 50 cells per mouse to make n ϭ 1).
Acetylcholinesterase (AChE) histochemistry was performed as described (42) . Briefly, microdissected jejunal tunica muscularis was incubated in acetylthiocholine iodide for 30 min to generate a product with peroxidase activity within the tissue. Subsequently the tissue was incubated with 3,3Ј-diaminobenzidine and nickel ammonium sulfate for 5 min prior to addition of 0.003% H 2O2 for 10 min to yield a dark precipitate on cholinergic neurons.
Ki-67 immunohistochemistry for proliferating cells was performed using a rat anti-mouse Ki-67 antibody (TEC-3, Dako, Glostrup, Denmark), as reported previously (15, 40) . For proliferation, an average of 20 half-crypts per mouse were counted in a blinded manner (to make n ϭ 1), with the cell at the base of the crypt designated cell 1. Half-crypts were defined as one side of the crypt compartment starting from the base of the crypt and were used to prevent redundant analysis of each crypt unit. Proliferation was determined as the proportion of Ki-67-positive cells relative to the total number of cells at each cell position. Uptake of BrdU was determined by antigen retrieval of tissue sections using 0.4% pepsin in 0.01 N HCl, followed by incubation with a mouse anti-BrdU antibody (1:1,000; Sigma Chemical, St. Louis, MO) and then with a biotinylated goat antimouse antibody (Vector Laboratories) and detection using 3,3Ј-diaminobenzidine. Positive cells were counted as described for Ki-67. Crypt and villus cell apoptosis was determined by using an antiserum directed against cleaved (active) caspase-3 (Cell Signaling, Danvers, MA) followed by a biotinylated goat anti-rabbit secondary (Vector Laboratories, Burlingame, CA) and detection using 3,3Ј-diaminobenzidine. In contrast to the proliferative cells, the number of apoptotic cells was low, and the total cells per crypt and per villus were therefore determined across four tissue sections from each mouse, and the results were expressed relative to the total number of crypts or villi counted.
Mucin histochemistry was performed with the Rapid Mucin Stain kit (Polysciences, Warrington, PA) according to the manufacturer's instructions. At least 20 half-villi were counted per mouse (to make n ϭ 1). As for the half-crypts, half-villi were defined as one side of the villus and were used to prevent redundant analysis of the villus compartment. Synaptophysin immunofluorescence was conducted using polyclonal rabbit anti-human synaptophysin antibody (1:200 dilution, Dako) as the primary antibody, 5% normal donkey serum as the blocking solution, and Cy3-conjugated Affinipure donkey antirabbit IgG (Jackson Immunoresearch Laboratories, West Grove, PA) as the secondary antibody. At least 20 half-villi were counted per mouse (to make n ϭ 1). Serotonin immunohistochemistry was performed using polyclonal rabbit serotonin antiserum as the primary antibody (Covance Research Products, Berkeley, CA) with biotinylated goat anti-rabbit secondary (Vector Laboratories), followed by detection with 3,3Ј-diaminobenzidine. At least 20 half-villi were counted per mouse (to make n ϭ 1).
Quantitative and RT-PCR. One-centimeter sections of proximal jejunum (11 cm from the pyloric sphincter) were snap-frozen in liquid nitrogen and stored at Ϫ80°C until homogenization in RLT RNA preservation buffer (Qiagen, Mississauga, ON, Canada) and RNA extraction. Strips of tunica muscularis were sonicated in RLT buffer and stored at Ϫ80°C until use. RNA was isolated with the RNeasy kit (Qiagen) according to the manufacturer's instructions. Some tissue samples were analyzed by RT-PCR using a One-Step kit (from Qiagen). The RT-PCR primers and conditions have been reported previously (27, 40) . Other samples were reverse-transcribed to cDNA with Superscript II Reverse Transcriptase (Invitrogen, Burlington, ON, Canada). Quantitative RT-PCR (qRT-PCR) was performed in a Chromo4 Continuous Fluorescence Detection unit with Opticon Monitor 3 software (Bio-Rad Laboratories, Mississauga, ON, Canada) using Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA), as listed in Table 1 (because the data for the GLP-2R exons 3-4 was not different than that for exons 11-12, only the latter is shown). All reactions were performed in triplicate, and control reactions were performed without RT enzyme and/or without template. The linearity of amplification of the Taqman primer-probe sets was verified over four orders of magnitude. Expression was calculated relative to the internal control, 18S rRNA, which was selected because we have previously shown that it is not affected by chronic GLP-2 administration (15). Relative transcript expression was calculated according to the ␦␦CT method (34), whereby the difference in cycle threshold (␦C T) of the transcript of interest and the internal control were divided for each animal to make n ϭ 1.
Functional analyses. To examine total GI transit, overnight-fasted, age-and sex-matched GFR␣2 WT and KO littermates were injected intraperitoneally with 0.15 g/g body wt [Gly 2 ]GLP-2, 0.06 g/g body wt GLP-1, or an equivalent volume of PBS; these peptide doses were selected based on the results of preliminary studies. Five minutes after injection, mice were gavaged (10 ml/kg) with 5% activated charcoal in 10% gum arabic (12) . Twenty minutes later the animals were euthanized and the transit of the charcoal solution along the length of the GI tract was assessed visually with a ruler under constant tension. Gastric emptying was determined by spectrophotometric analysis (at 405 nm) of phenol red remaining in the stomach of fasted mice 20 min after oral gavage of 0.1 mg/ml phenol red, as per the protocol of Crowell et al. (8) . Exendin-4 (0.1 g ip; Bachem California, Torrance, CA)-induced suppression of 8-h food intake was determined in fasted mice, as previously reported (43) .
Statistical analysis. All statistical analyses were conducted with Prism 4.00 software (GraphPad Software, San Diego, CA). Student's t-test or one-or two-way ANOVA was performed, as appropriate. ANOVA was followed, when significant, by post hoc comparisons using Student's t-test or one-way ANOVA.
RESULTS

Characterization of the ENS in GFR␣2 KO mice. GFR␣2
WT, HT, and KO animals were identified by PCR of tail DNA (Fig. 1A) , and qRT-PCR of microdissected tunica muscularis confirmed the absence of GFR␣2 mRNA in KO animals (Fig.  1B) . Histochemical staining of the tunica muscularis for AChE also demonstrated decreased cholinergic fiber staining in KO mice relative to WT controls (Fig. 1C) .
The presence of mRNA transcripts for both the GLP-1 and the GLP-2 receptor in microdissected tunica muscularis was demonstrated by RT-PCR ( Fig. 2A) . The same tissues did not express mRNA for an epithelial endocrine cell marker, proglucagon (control), indicating the specificity of the separation technique. Knockout of GFR␣2 was not associated with changes in mRNA transcript levels for the parasympathetic cholinergic marker vesicular acetylcholine transporter (VAChT), the more general cholinergic marker AChE, or the general neural marker ␤-tubulin 3 (BT3) in microdissected tunica muscularis (Fig. 2B) . However, expression of mRNA transcripts for the excitatory neurotransmitter SP was significantly reduced in KO mice (by 37 Ϯ 11%, P Ͻ 0.05). No difference was observed in mRNA transcript levels for VIP (Fig. 2C) , nor was there differential expression of GLP-1R or GLP-2R mRNA transcripts in tunica muscularis from the KO animals (Fig. 2D) .
Effects of chronic GLP-2 administration. The body weight of age-and sex-matched KO mice was significantly lower than that of WT animals (18.2 Ϯ 0.6 vs. 16.0 Ϯ 0.8, P Ͻ 0.05), likely due to general parasympathetic denervation as reported for an independent line of GFR␣2 KO mice (37) . Subcutaneous administration of [Gly 2 ]GLP-2 daily for 14 days significantly increased small intestinal wet weight relative to body weight in WT, HT, and GFR␣2 KO mice (Fig. 3A, P Ͻ 0.001) . A similar trend was seen in the large intestine (Fig. 3B) . Small intestinal villus height (P Ͻ 0.001, Fig. 3C ) was also increased by chronic administration of [Gly 2 ]GLP-2, although only a trend toward increased crypt depth was observed (Fig. 3D) . However, no effects of GFR␣2 KO were observed in any of these parameters of epithelial growth, and no differential effect of GLP-2 administration was seen between groups. Surprisingly, despite the increased small intestinal weight and cryptvillus height, no effect of GLP-2 was seen on small intestinal crypt cell proliferation in WT or KO animals, as determined by Ki-67 staining (Fig. 3, E and F) and, again, no differences between WT and KO mice were noted. Furthermore, analysis of BrdU uptake by the crypt cells revealed a similar profile as found for Ki-67 (with peak values of 0.55 Ϯ 0.04 cells at positions 9 -11) and, again, did not reveal any differences between saline-and GLP-2-treated WT or KO mice (data not shown). Determination of changes in crypt and villus cell apoptosis similarly did not reveal any differences due to GLP-2 treatment, although it is noted that the number of cells detectable in the normal mouse intestine was extremely low (only 1.1 Ϯ 0.3% of all crypts and 9.8 Ϯ 3.0% of all villi were found to contain any caspase-3-positive cells), making quantitative demonstration of any differences difficult. Finally, analysis of cell size did not demonstrate any significant differences in either cell width or length (5.1 Ϯ 0.3 and 20.0 Ϯ 0.9 m, respectively, in WT-PBS mice) in response to GLP-2 treatment or in KO animals.
To determine the effects of GLP-2 and GFR␣2 KO on lineage differentiation of the intestinal epithelium, histochemistry for the mucous cell product, mucin, and immunohisto- Gene expression assays were from Applied Biosystems. AChE, acetylcholinesterase; GFR␣2, glial cell line-derived neurotropic factor family receptor ␣2; R, receptor; SP, substance P; VAChT, vesicular acetylcholine transporter; VIP, vasoactive intestinal peptide. chemistry for both the enteroendocrine cell marker, synaptophysin, and enterochromaffin cells was performed. A significant increase in the number of mucin cells per villus was seen with GLP-2 treatment in WT mice (P Ͻ 0.05), and a similar trend was observed in synaptophysin-positive staining, concomitant with the increases observed in villus length (Fig. 4, A and B) . Unexpectedly, significantly fewer synaptophysin-positive cells were observed in the villi of PBS-treated GFR␣2 KO mice relative to PBS-WT animals (P Ͻ 0.05), and GLP-2 treatment partially reversed this deficit (P Ͻ 0.05). Serotonin-positive cell numbers in the jejunum equaled ϳ70% of the total synaptophysin-positive enteroendocrine cells (Fig.  4C) . Furthermore, in keeping with the changes in synaptophysin positivity, the number of serotonin cells was increased by GLP-2 treatment of WT mice (P Ͻ 0.05), and there was a similar trend to decreased cell numbers in the KO animals.
Effects of acute administration of the glucagon-like peptides on GI transit and food intake. In WT mice, intraperitoneal administration of 0.15 g/g [Gly 2 ]GLP-2 caused a significant reduction in GI transit of a charcoal solution relative to treatment with vehicle alone (by 29 Ϯ 8%, P Ͻ 0.05). GLP-1 (0.06 g/g) administration also significantly impaired transit of the gavaged charcoal solution in WT animals (by 55 Ϯ 4%, P Ͻ 0.001). GFR␣2 KO mice exhibited decreased basal transit with vehicle administration relative to WT controls (by 37 Ϯ 6%, P Ͻ 0.01); however, in contrast to their effects in WT animals, neither GLP-2 nor GLP-1 further reduced transit rates in KO mice (Fig. 5A ). To determine whether the impairment in GI transit in KO animals was due to alterations in gastric emptying and/or intestinal motility, the retention of phenol red in the stomach was determined following oral gavage. No significant differences were observed between WT and KO mice, suggesting that the changes in GI transit observed in KO animals occurred consequent to altered intestinal motility (Fig. 5B) . To further determine whether general vagal tone was altered in the KO animals, mice were administered a long-acting GLP-1 agonist, exendin-4, that we have previously demonstrated to inhibit food intake in mice through a vagal-dependent mechanism (43) . No differences in exendin-4-induced reductions in food intake were observed between WT and KO animals (Fig. 5C ).
DISCUSSION
Despite more than a decade of research, the sites and mechanisms of action of the glucagon-like peptides within the intestine remain controversial and poorly understood. GLP-1 exerts a profound inhibitory effect on GI motility, yet the role of the GLP-1R in the intestine has never been explicitly studied. Meanwhile, several locations have been demonstrated for the GLP-2R within the intestinal mucosa and ENS, but the contributions of each to the biological effects of GLP-2 have not been confirmed. To better understand the actions of the glucagon-like peptide receptors in the ENS, we employed a model of partial enteric nervous deficit, the GFR␣2 KO mouse. In this context, we hypothesized that GFR␣2 KO mice would exhibit reduced mucosal growth in response to GLP-2 and impaired inhibition of gut motility by GLP-1 and/or GLP-2. The results of this study demonstrate that, although loss of GFR␣2 abrogates the ability of both glucagon-like peptides to inhibit GI transit, there is no differential intestinotropic response to GLP-2 in GFR␣2 KO mice.
Histochemical analysis of acetylcholinesterase distribution in microdissected tunica muscularis revealed a dramatic reduction in staining for small fibers in GFR␣2 KO mice, as previously reported for a similar mouse model (37) . Characterization of mRNA expression in the tunica muscularis by qRT-PCR further demonstrated that SP transcript levels were decreased by 35%, consistent with the results of immunohistochemical analyses showing reduced substance P-positive fiber density in other GFR␣2-deficient animals (37). In contrast, mRNA transcript levels for the more general markers of cholinergic innervation, including VAChT, AChE, and BT3, were not altered by GFR␣2 KO. These findings accord with our current understanding of the ENS, in that substance P-ergic neurons represent only a small proportion (ϳ12-25%) of the total cholinergic neurons in the plexus (16) . Thus, GFR␣2 KO would not be expected to result in a profound reduction in either general cholinergic or neural markers of the entire ENS. Furthermore, the reduced cholinergic fiber staining did not appear to be associated with a demonstrable loss of cholinergic soma, where most gene expression occurs, which accounts for the apparent discrepancy between the histochemical and gene expression analyses. Finally, as VIP and SP or ACh have not been colocalized in the ENS (16) , no change in VIP expression was expected in the GFR␣2 KO mouse, nor was any such change observed. Taken together, therefore, the results of the present study confirm that GFR␣2 KO results in a highly selective deficit of the cholinergic/substance P fibers that constitute one component of the excitatory enteric neural input to the longitudinal muscle of the small intestine (16, 25) . These findings are consistent with reduced basal intestinal transit rates in these animals, as found in the present study and previously reported for other GFR␣2 KO mice (36) .
Administration of GLP-1 prior to oral gavage of a charcoal solution significantly reduced GI transit in WT mice, in keeping with the well-characterized ability of GLP-1 to inhibit both gastric emptying and intestinal motility (5, 19, 21, 45) . However, GLP-1 did not reduce GI transit below baseline in the GFR␣2 KO mice. Studies using vagal deafferentation and vagotomy have demonstrated that the vagus is an important site at which GLP-1 inhibits gastric emptying (21, 47) . However, GFR␣2 KO mice did not demonstrate any reductions in gastric emptying, nor did they exhibit an impaired response to vagaldependent exendin-4-induced reductions in food intake. It is therefore likely that the loss of the inhibitory effect of GLP-1 in the KO mice is due to their deficiency in excitatory myenteric innervation in the small intestine. Finally, the localization of GLP-1R expression to the jejunal tunica muscularis suggests a local role for GLP-1 in the inhibition of gut motility, whereas the absence of an inhibitory response in KO mice demonstrates that GLP-1 does not act directly on the smooth muscle.
Given the lack of effect of GLP-1 on GI transit in GFR␣2 KO mice, it was somewhat unexpected that no decrease in Fig. 3 . Effect of GFR␣2 KO and chronic GLP-2 administration on parameters of intestinal growth. A-D: WT, HT, and KO mice were administered 0.15 g/g body wt GLP-2 daily for 14 days, followed by tissue collection on day 15. Small (A) and large (B) intestinal wet weight per body weight, and jejunal villus height (C) and crypt depth (D) (nϭ 10 for all groups). E-F: WT and KO mice were administered 0.15 g/g body wt GLP-2 daily for 14 days, followed by tissue collection on day 15 . Small intestinal crypt cell Ki-67 positivity was determined along the length of the crypt, with the cell at the base defined as position 1. *P Ͻ 0.05 and ***P Ͻ 0.001 for GLP-2 vs. saline treatment within the same genotype.
GLP-1R mRNA transcript levels in the ENS could be detected in these animals. However, prior studies have demonstrated that adrenergic blockers abolish the effect of GLP-1 on intestinal motility (19) , suggesting that GLP-1 may act via presynaptic inhibition of cholinergic transmission. One model to explain the absence of a GLP-1 effect in the GFR␣2 KO mice is that the GLP-1R is located on postganglionic sympathetic efferents in the gut that inhibit descending cholinergic motoneurons. GLP-1 signaling in this model would thus prevent cholinergic stimulation of excitatory GFR␣2-expressing cholinergic/substance P neurons, with loss of these fibers resulting in abrogation of GLP-1-mediated transit inhibition. Future studies using animals that lack selective components of this signaling pathway will be required to confirm this mechanism of GLP-1-mediated inhibition of intestinal motility.
Similar to the findings made with GLP-1, administration of GLP-2 was found to inhibit GI transit in WT mice. Interestingly, the dose of [Gly 2 ]GLP-2 that inhibited transit by 29% in these animals was markedly higher than that of GLP-1, which resulted in 55% inhibition (0.15 vs. 0.06 g/g body wt, respectively). This difference in potency was further magnified by our use of a degradation-resistant analog of GLP-2 (44) compared with the very rapidly degraded native form of GLP-1 (9) . Consistent with our findings, previous studies have demonstrated that the effects of GLP-2 on antral motility are markedly less potent than those of GLP-1 (29) . However, the only prior study of GLP-2 and small intestinal motility in rodents has shown an additive effect of GLP-2 to augment GLP-1 inhibition of motility but no independent actions of GLP-2 (5). Furthermore, as also found for GLP-1, GLP-2 failed to inhibit GI transit in GFR␣2 KO mice, despite the presence of GLP-2R mRNA transcripts in the tunica muscu- 5 . Effect of GFR␣2 KO and acute GLP administration on gastrointestinal (GI) function and food intake. A: fasted WT and KO littermates were administered 0.06 g/g body wt GLP-1, 0.15 g/g body wt GLP-2, or an equivalent volume of saline ip at t ϭ Ϫ5 min, followed by oral gavage with a charcoal solution at t ϭ 0 min, and determination of GI transit at t ϭ 20 min (n ϭ 4 -10). B: fasted WT and KO mice were given phenol red by orogastric gavage and the content remaining in the stomach after 20 min was determined spectrophotometrically (n ϭ 4 -6). C: fasted WT and KO mice were treated with or without 0.1 g of exendin-4, and cumulative food intake was determined over an 8 h period (n ϭ 3). *P Ͻ 0.05 for GLP vs. saline treatment within the same genotype; ϩP Ͻ 0.05 for KO vs. WT with saline treatment.
laris. Although Guan et al. (20) have colocalized the GLP-2R to enteric neurons expressing VIP, hallmarks of inhibitory motoneurons (16) , no reduction in VIP-expressing neurons was detected in the present study. However, it is possible that GLP-2 mediates its anti-transit effect by inhibiting the release of a factor such as serotonin, thereby reducing excitatory cholinergic transmission of the GI tract. This is consistent with the demonstration of GLP-2R expression on serotonin-expressing enterochromaffin cells in the mucosa (48) that are known to stimulate intestinal motility in response to luminal stimuli (18) . Interestingly, the majority of synaptophysin-expressing enteroendocrine cells in the mouse jejunum were represented by enterochromaffin cells, as also reported by others (35) , and these were reduced in number in the GFR␣2 KO mice. The mechanisms underlying these changes are not known but may provide an explanation for the inability of GLP-2 to inhibit motility in the GFR␣2-deficient animals. A relationship between GLP-2, enterochromaffin cells, and intestinal transit has been further suggested by a recent study demonstrating that ileitis increases the numbers of colonic GLP-2-and serotoninexpressing cells in association with colonic hyperexcitability (31). Nonetheless, it remains possible that GLP-2 exerted its effects through a GLP-1R-dependent pathway in the gut, as suggested by others (5) . For example, the ability of the structurally related peptide, glicentin, to inhibit colonic smooth muscle motility is blocked by the GLP-1R antagonist ex- Although GLP-2 has been demonstrated to activate tetrodotoxin-dependent c-fos expression in crypt cells, leading to the suggestion that the enteric GLP-2R is important for the intestinotropic effects of GLP-2 (3), no differential growth responses to GLP-2 administration were found in GFR␣2 KO mice. The simplest interpretation for this is that the growth effects of GLP-2 are not directly mediated by receptor signaling in the ENS. Several lines of evidence suggest that this may be the case. First, the GLP-2R has recently been sublocalized to vasodilatory and/or inhibitory motoneurons that do not project to the intestinal epithelium (4, 16) . Secondly, recent studies have demonstrated that the intestinotropic actions of GLP-2 are mediated by growth factors, such as insulin-like growth factor-1, insulin-like growth factor-2, and keratinocyte growth factor, that arise from the intestinal mucosa (15, 32) , rather than by enteric neurotransmitters/neuropeptides. Nonetheless, because there was no decrease in GLP-2R expression in the tunica muscularis of KO animals, it remains possible that the ENS may mediate some of the intestinotropic effect of GLP-2 indirectly. Furthermore, a very recent study has implicated the submucosal GLP-2R in GLP-2 effects on crypt cell proliferation in rodent models of inflammation (41) . This finding suggests that the present model of myenteric deficit may not have been optimal to investigate the tropic effects of GLP-2.
Studies in other murine models have demonstrated that GLP-2 stimulates intestinal growth in the small intestine, as well as in the colon, although greatest effects are typically observed in the jejunum (46) . These actions of GLP-2 in the normal mouse intestine are thought to be mediated, at least in part, through enhancement of crypt cell proliferation (14, 15) . However, despite the increase in both intestinal weight and villus height observed in response to treatment with GLP-2, no enhancement of crypt cell proliferation could be detected in the present study, as determined by both Ki-67 staining and BrdU uptake. Interestingly, the GFR␣2 mice were studied on a mixed C57Bl/6 ϫ 129Sv/J background, and a similar absence of effect of GLP-2 to increase Ki-67 positivity has been observed in mice on a pure 129Sv/J background, compared with the stimulatory effects of GLP-2 that were observed in identically treated CD1 animals (15) . Collectively, these findings provide further support for the notion of strain-specific differences in proliferation in response to chronic administration of GLP-2 in mice (15) . As to the mechanisms underlying the GLP-2-induced small increase in villus height in both the WT and KO animals, no effect to reduce apoptosis or increase cell width was detected. However, the effects of GLP-2 on detachmentinduced cell anoikis, as well as on villus cell necrosis remain unknown, and changes in these parameters may well contribute to the increased jejunal villus height observed in GLP-2-treated mice. When taken together, these findings suggest that 129Sv/J mice may be an interesting model whereby to study nonproliferative growth effects of GLP-2. Finally, all of the GLP-2-induced changes in differentiated cell numbers were found to occur in parallel with the increases in villus height, suggesting that GLP-2 had no effect on cell lineage differentiation. Similar results have been reported by others for the effects of GLP-2 on small intestinal mucus cell numbers (3) .
In summary, the results of the present study demonstrate a role for GFR␣2-expressing enteric neurons in the downstream signaling of the glucagon-like peptides to inhibit GI motility but do not show a role for these neurons in either basal or GLP-2-stimulated intestinal growth. A better understanding of the mechanism of action of the glucagon-like peptides in the intestine may lead to novel therapeutic approaches to treat patients with disordered intestinal motility.
